<DOC>
	<DOCNO>NCT00492752</DOCNO>
	<brief_summary>The purpose study - Find patient receive Sorafenib live long - Find Sorafenib effect patient report outcome - Find Sorafenib prevent growth shrink liver tumor / metastasis - Determine pharmacokinetics ( PK ) patient liver cancer</brief_summary>
	<brief_title>A Randomized , Double-Blinded , Placebo-Controlled Study Sorafenib Patients With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Ages eligible study : 18 year , Genders eligible study : Patients life expectancy least 12 week Patients advance Hepatocellular carcinoma ( HCC ) ( unresectable , and/or metastatic ) histologically cytologically documented Patients must least one tumor lesion meet follow criterion 1 . Accurately measure least one dimension accord Response Evaluation Criteria Solid Tumors ( RECIST ) 2 . Not previously treat local therapy Patients receive local therapy , surgery , radiation therapy , hepatic arterial embolization , chemoembolization , radiofrequency ablation , percutaneous ethanol injection cryoablation eligible . Previously treat lesion select target lesion . Local therapy must complete least 4 week prior baseline scan Patients Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 , 2 Previous concurrent cancer distinct primary site histology HCC , EXCEPT cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor ( Ta [ Noninvasive papillary carcinoma ] , Tis [ Carcinoma situ : `` flat tumor '' ] &amp; T1 [ Tumor invade subepithelial connective tissue ] ) . Any cancer curatively treat &gt; 3 year prior entry permitted History cardiac disease Active clinically serious infection Known history human immunodeficiency virus ( HIV ) infection Known central nervous system ( CNS ) tumor include metastatic brain disease Patients clinically significant gastrointestinal bleeding within 30 day prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>